Richmond Pharmacology announces its attendance at TIDES Europe 2025 in Basel, one of the leading global conferences dedicated to oligonucleotide- and peptide-based therapeutics.

This year’s meeting will bring together experts from across the world to discuss advances in discovery, development, and clinical translation of RNA, DNA, and peptide therapeutics.

 

Representing Richmond Pharmacology:
Stephen Wilkinson, Business Development Manager

 

Stephen looks forward to engaging with industry leaders, researchers, and clinical partners to explore opportunities in:
• Early-phase trials for oligonucleotide and peptide therapies
• Rare and metabolic disease clinical research
• Regulatory strategy and scientific advice
• Innovative patient recruitment models
• Adaptive and patient-centric trial design

 

If you are attending TIDES Europe and would like to learn how Richmond Pharmacology can support your oligonucleotide and peptide therapeutic development, we welcome you to connect with us during the event.

 

For meeting requests or collaboration enquiries:
📧info@richmondpharmacology.com

 

Learn more about the event: TIDES Europe: Oligonucleotide and Peptide Therapeutics

Latest news

Richmond Pharmacology Appoints Patrick Ramiah as Director of Clinical Project Delivery & Operational Excellence

September 1, 2025
Richmond Pharmacology is delighted to announce the promotion of Patrick Ramiah to the role of Director of Clinical Project Delivery & Operational Excellence, effective from 1 September 2025.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event